Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Inhibition of the BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma. However, colon cancer patients harbouring the same BRAF(V600E) oncogenic lesion have poor prognosis and show only a very limited response to this drug. To investigate the cause of the limited therapeutic effect of PLX4032 in BRAF(V600E) mutant colon tumours, here we performed an RNA-interference-based genetic screen in human cells to search for kinases whose knockdown synergizes with BRAF(V600E) inhibition. We report that blockade of the epidermal growth factor receptor (EGFR) shows strong synergy with BRAF(V600E) inhibition. We find in multiple BRAF(V600E) mutant colon cancers that inhibition of EGFR by the antibody drug cetuximab or the small-molecule drugs gefitinib or erlotinib is strongly synergistic with BRAF(V600E) inhibition, both in vitro and in vivo. Mechanistically, we find that BRAF(V600E) inhibition causes a rapid feedback activation of EGFR, which supports continued proliferation in the presence of BRAF(V600E) inhibition. Melanoma cells express low levels of EGFR and are therefore not subject to this feedback activation. Consistent with this, we find that ectopic expression of EGFR in melanoma cells is sufficient to cause resistance to PLX4032. Our data suggest that BRAF(V600E) mutant colon cancers (approximately 8-10% of all colon cancers), for which there are currently no targeted treatment options available, might benefit from combination therapy consisting of BRAF and EGFR inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF inhibition in BRAFV600 mutant cancers leads to loss of negative feedback signals regulated by the MAPK pathway, leading to receptor tyrosine kinase (RTK)-mediated reactivation of MAPK signaling through wild type RAS and RAF, particularly in specific tumor types, such as colorectal cancer (9–12).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, RTK-driven feedback reactivation of RAS-MAPK signaling has been identified as a key driver of resistance in BRAFV600E cancers treated with BRAF inhibitors (colorectal cancer in particular) and in KRAS-mutant cancers treated with MEK inhibitors (11,12,32).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This finding is consistent with prior studies identifying HER family and FGFR signaling as key mediators of adaptive feedback to RAS-MAPK pathway inhibitors (10–14,21,22) and recent functional genomic screens(40).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, adaptive feedback resistance has been a key limitation in prior clinical efforts to target the RAS-MAPK pathway.”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prevalence of BRAF V600E mutations in mCRC is 8–10%, and they occur only in KRAS-WT mCRC [159,160].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [159]
Experimental — accuracy not yet measured
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“shRNA inserts were retrieved from 8mg genomic DNA by PCR amplification (PCR1 and PCR2, see below for primer information) using the following conditions: (1) 98 uC, 30 s; (2) 98 uC, 10 s; (3) 60 uC, 20 s; (4) 72 uC, 1 min; (5) to step (2), 15 cycles; (6) 72 uC, 5 min; (7) 4 uC.”
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“Figure 1e shows that inhibition of EGFR does not significantly affect proliferation of EGFR in WiDr cells, consistent with the clinical observations that KRAS or BRAF mutant CRC cells do not respond to EGFR-targeted monoclonal antibodie”
ResultEpidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,707
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 1×
“shRNA inserts were retrieved from 8mg genomic DNA by PCR amplification (PCR1 and PCR2, see below for primer information) using the following conditions: (1) 98 uC, 30 s; (2) 98 uC, 10 s; (3) 60 uC, 20 s; (4) 72 uC, 1 min; (5) to step (2), 15 cycles; (6) 72 uC, 5 min; (7) 4 uC.”
Self-citationThe Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,158
Cited by
Items 801–900 of 1,012
Building high-resolution synthetic lethal networks: a ‘Google map’ of the cancer cell
Paul, J., Templeton, S. D., Baharani, A., Freywald, A., & Vizeacoumar, F. J. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.09.009 · Cited by 39
Mikhitarian, K., Pollen, M., Zhao, Z., Shyr, Y., Merchant, N. B., Parikh, A. A., Revetta, F. L., Washington, M. K., Vnencak‐Jones, C. L., & Shi, C. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.185 · Cited by 35
Al-Marrawi, M. Y., Saroya, B. S., Brennan, M., Yang, Z., Dykes, T. M., & El‐Deiry, W. S. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.25191 · Cited by 34
Logic Modeling in Quantitative Systems Pharmacology
Traynard, P., Tobalina, L., Eduati, F., Calzone, L., & Sáez-Rodríguez, J. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12225 · Cited by 38
Antonello, Z. A., & Nucera, C. (2013) · Oncogene · doi:10.1038/onc.2013.544 · Cited by 34
Sherman, S. I. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.03.442 · Cited by 33
Update on systemic therapy for colorectal cancer: biologics take sides
Gbolahan, O. B., & O’Neil, B. H. (2019) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.01.12 · Cited by 34
Oncoprotein-specific molecular interaction maps (SigMaps) for cancer network analyses
Broyde, J., Simpson, D. R., Murray, D., Paull, E., Chu, B., Tagore, S., Jones, S. J., Griffin, A. T., Giorgi, F. M., Lachmann, A., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0652-7 · Cited by 33
How Should Cancer Models Be Constructed?
Beckman, R. A., Kareva, I., & Adler, F. R. (2020) · Cancer Control · doi:10.1177/1073274820962008 · Cited by 36
CRISPR screens identify tumor‐promoting genes conferring melanoma cell plasticity and resistance
Gautron, A., Bachelot, L., Aubry, M., Leclerc, D., Quéméner, A. M., Corre, S., Rambow, F., Paris, A., Tardif, N., Leclair, H. M., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013466 · Cited by 37
Receptor tyrosine kinases in cancer escape from BRAF inhibitors
Lo, R. S. (2012) · Cell Research · doi:10.1038/cr.2012.78 · Cited by 34
Tahiri, A., Redalen, K. R., Ree, A. H., de Wijn, R., Risberg, K., Busch, C., Lønning, P. E., Kristensen, V. N., & Geisler, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072692 · Cited by 33
High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells
Horn, T. L., Ferretti, S., Ebel, N., Tam, A., Ho, S. B., Harbinski, F., Farsidjani, A., Zubrowski, M. J., Sellers, W. R., Schlegel, R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3425 · Cited by 36
Kotani, H., Adachi, Y., Kitai, H., Tomida, S., Bando, H., Faber, A. C., Yoshino, T., Voon, D. C., Yano, S., & Ebi, H. (2018) · Oncogene · doi:10.1038/s41388-017-0035-9 · Cited by 35
Kim, S. Y., & Kim, T. W. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000634 · Cited by 35
Update: The Status of Clinical Trials With Kinase Inhibitors in Thyroid Cancer
Wells, S. A., & Santoro, M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2622 · Cited by 35
The dream and reality of histology agnostic cancer clinical trials
Lacombe, D., Burock, S., Bogaerts, J., Schoeffski, P., Golfinopoulos, V., & Stupp, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.06.002 · Cited by 32
An siRNA screen identifies the GNAS locus as a driver in 20q amplified breast cancer
García-Murillas, I., Sharpe, R., Pearson, A., Campbell, J., Natrajan, R., Ashworth, A., & Turner, N. C. (2013) · Oncogene · doi:10.1038/onc.2013.202 · Cited by 33
New therapeutic strategies for BRAF mutant colorectal cancers.
Corcoran, R. B. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2015.076 · Cited by 35
Borovski, T., Vellinga, T. T., Laoukili, J., Santo, E. E., Fátrai, S., van Schelven, S., Verheem, A., Marvin, D. L., Ubink, I., Rinkes, I. H. M. B., et al. (2016) · Gut · doi:10.1136/gutjnl-2016-311547 · Cited by 34
Schmoll, H., Arnold, D., de Gramont, A., Ducreux, M. P., Grothey, A. F., O'Dwyer, P. J., Cutsem, E. V., Hermann, F., Bosanac, I., Bendahmane, B., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2632-6 · Cited by 34
Genomics-guided pre-clinical development of cancer therapies
Francies, H. E., McDermott, U., & Garnett, M. J. (2020) · Nature Cancer · doi:10.1038/s43018-020-0067-x · Cited by 34
Efficient blockade of locally reciprocated tumor-macrophage signaling using a TAM-avid nanotherapy
Wang, S. J., Li, R., Ng, T. S. C., Luthria, G., Oudin, M. J., Prytyskach, M., Köhler, R. H., Weissleder, R., Lauffenburger, D. A., & Miller, M. A. (2020) · Science Advances · doi:10.1126/sciadv.aaz8521 · Cited by 36
The Emerging Role of Ras Pathway Signaling in Pediatric Cancer
Ney, G. M., McKay, L. M., Koschmann, C. J., Mody, R. J., & Li, Q. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0916 · Cited by 36
Targeting DNA Repair, Cell Cycle, and Tumor Microenvironment in B Cell Lymphoma
Bröckelmann, P. J., de Jong, M. R. W., & Jachimowicz, R. D. (2020) · Cells · doi:10.3390/cells9102287 · Cited by 34
Theiss, A. P., Chafin, D. R., Bauer, D. R., Grogan, T. M., & Baird, G. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113608 · Cited by 33
Dissecting cancer heterogeneity – An unsupervised classification approach
Wang, X., Markowetz, F. M., Melo, F. D. S. E., Medema, J. P., & Vermeulen, L. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.08.014 · Cited by 35
EGFR blockade prevents glioma escape from BRAFV600E targeted therapy
Yao, T.-W., Zhang, J., Prados, M. D., Weiss, W. A., James, C. D., & Nicolaides, T. P. (2015) · Oncotarget · doi:10.18632/oncotarget.4014 · Cited by 34
Watanabe, Y., Shido, K., Niihori, T., Niizuma, H., Katata, Y., Iizuka, C., Oba, D., Moriya, K., Saito‐Nanjo, Y., Onuma, M., et al. (2015) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.37376 · Cited by 32
A framework for genomic biomarker actionability and its use in clinical decision making
Vidwans, S. J., Turski, M. L., Jankú, F., Garrido‐Laguna, I., Munoz, J., Schwab, R. B., Subbiah, V., Rodon, J. A., & Kurzrock, R. (2014) · Oncoscience · doi:10.18632/oncoscience.90 · Cited by 33
CXCR7 promotes melanoma tumorigenesis via Src kinase signaling
Xu, S., Tang, J., Wang, C., Liu, J., Fu, Y., & Luo, Y. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1442-3 · Cited by 34
Damato, A., Iachetta, F., Antonuzzo, L., Nasti, G., Bergamo, F., Bordonaro, R., Maiello, E., Zaniboni, A., Tonini, G., Romagnani, A., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07268-4 · Cited by 34
Attiq, A., & Afzal, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1255727 · Cited by 33
Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet
McArthur, G. A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00161 · Cited by 34
Xu, L., Cai, J., Yang, Q., Ding, H. J., Wu, L., Li, T., & Wang, Z. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1435-z · Cited by 31
Gilson, C., Chowdhury, S., Parmar, M., & Sydes, M. R. (2017) · Clinical Oncology · doi:10.1016/j.clon.2017.10.004 · Cited by 32
HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance
Loria, R., Laquintana, V., Bon, G., Trisciuoglio, D., Frapolli, R., Covello, R., Amoreo, C. A., Ferraresi, V., Zoccali, C., Novello, M., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0394-x · Cited by 33
RNA Interference-Based Cancer Drugs: The Roadblocks, and the “Delivery” of the Promise
Das, M., Musetti, S., & Huang, L. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0762 · Cited by 32
BRAF Mutation and Its Importance in Colorectal Cancer
Luu, L., & Price, T. J. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82571 · Cited by 33
Yoshitake, R., Saeki, K., Eto, S., Shinada, M., Nakano, R., Sugiya, H., Endo, Y., Fujita, N., Nishimura, R., & Nakagawa, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-64832-5 · Cited by 33
Peppicelli, S., Andreucci, E., Ruzzolini, J., Bianchini, F., Nediani, C., Supuran, C. T., & Calorini, L. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1764549 · Cited by 31
Florou, V., Nevala-Plagemann, C., Whisenant, J. R., Maeda, P., Gilcrease, G. W., & Garrido‐Laguna, I. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.7022 · Cited by 32
Yang, L., Bhattacharya, A., Li, Y., Sexton, S., Ling, X., Li, F., & Zhang, Y. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02389-z · Cited by 32
Wei, S., Hu, W., Feng, J., & Geng, Y. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00960-x · Cited by 32
Sun, L., Yu, J., Guinney, J., Qin, B., & Sinicrope, F. A. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0552 · Cited by 33
Albano, G., Giorno, V., Román‐Román, P., Roman‐Roman, S., & Torres‐Ruiz, F. (2014) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2014.09.014 · Cited by 32
Proteomics and drug discovery in cancer
Dias, M. H., Kitano, E. S., Zelanis, A., & Iwai, L. K. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.10.004 · Cited by 37
Hoang, V. T., Nyswaner, K. M., Torres‐Ayuso, P., & Brognard, J. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.012365 · Cited by 33
MEK and RAF inhibitors for BRAF-mutated cancers
Belden, S. E., & Flaherty, K. T. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2012.11 · Cited by 31
Informatics Approaches for Predicting, Understanding, and Testing Cancer Drug Combinations
Tang, J. P. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7154-1_30 · Cited by 30
Battaglin, F., Dadduzio, V., Bergamo, F., Manai, C., Schirripa, M., Lonardi, S., Zagonel, V., & Loupakis, F. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1356815 · Cited by 74
Wang, D. Y. Q., Hensman, J. J., Kutkaite, G., Toh, T. S., Galhoz, A., GDSC Screening Team, Lightfoot, H. W., Yang, W., Soleimani, M., Barthorpe, S., et al. (2020) · eLife · doi:10.7554/elife.60352 · Cited by 30
Machine learning methods to model multicellular complexity and tissue specificity
Sealfon, R. S. G., Wong, A. K., & Troyanskaya, O. G. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00339-3 · Cited by 32
Recent advances and current issues in single-cell sequencing of tumors
Sun, H., Chen, J., Ni, B., Yang, X., & Wu, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.04.022 · Cited by 32
KRAS, BRAF, and TP53 Deep Sequencing for Colorectal Carcinoma Patient Diagnostics
Rechsteiner, M., von Teichman, A., Rüschoff, J. H., Fankhauser, N., Pestalozzi, B. C., Schraml, P., Weber, A., Wild, P. J., Zimmermann, D. R., & Moch, H. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.02.001 · Cited by 30
Human Correlates of Provocative Questions in Pancreatic Pathology
McDonald, O. G., Maitra, A., & Hruban, R. H. (2012) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e318273f998 · Cited by 33
Modelling signalling networks from perturbation data
Dorel, M., Klinger, B., Groß, T., Sieber, A., Prahallad, A., Bosdriesz, E., Wessels, L. F. A., & Blüthgen, N. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty473 · Cited by 30
Self-citationImprovements in Clinical Outcomes for BRAFV600E-Mutant Metastatic Colorectal Cancer
Morris, V. K., & Bekaii‐Saab, T. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3809 · Cited by 33
Su, X., Li, P., Han, B., Hao, J., Liang, Q., Wang, H., Gu, M., Cai, J., Li, S., Zhou, Y., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01831-y · Cited by 31
Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit
Ning, W., Marti, T. M., Dorn, P., & Peng, R.-W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1004669 · Cited by 29
Xie, J., Liu, J., Zhao, M., Li, X., Wang, Y., Zhao, Y., Cao, H., Ji, M., Chen, M., & Hou, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043418 · Cited by 29
“It has shown limited benefit in patients with thyroid and colorectal cancers [16,18,19].”
BackgroundXu, C., Qi, Y., Cui, Z., Yang, Y., Wang, J., Hu, Y., Yu, B., Wang, F.-Z., Yang, Q., & Sun, H.-T. (2019) · RSC Advances · doi:10.1039/c8ra09640f · Cited by 29
Somatic DNA mutation analysis in targeted therapy of solid tumours.
Yu, B., O'Toole, S. A., & Trent, R. J. (2015) · PubMed Central · doi:10.3978/j.issn.2224-4336.2015.04.04 · Cited by 33
Peng, U., Wang, Z., Pei, S., Ou, Y., Hu, P., Liu, W., & Song, J. (2016) · Oncology Reports · doi:10.3892/or.2016.5340 · Cited by 32
Kenessey, I., Kramer, Z., István, L., Cserepes, M., Garay, T., Hegedűs, B., Dobos, J., Tímár, J., & Tóvári, J. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000488 · Cited by 33
Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology
Gümüşay, Ö., Vitiello, P. P., Wabl, C. A., Corcoran, R. B., Bardelli, A., & Rugo, H. S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280845 · Cited by 33
Self-citationGarcía-Rendueles, M. E. R., Krishnamoorthy, G. P., Saqcena, M., Acuña-Ruíz, A., Revilla, G., de Stanchina, E., Knauf, J. A., Lester, R., Xu, B., Ghossein, R. A., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01676-9 · Cited by 31
Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers
Ros, J., Rodríguez-Castells, M., Gonzalez, N. S., Baraibar, I., Salvà, F., Tabernero, J. M., & Élez, E. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2236794 · Cited by 32
BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment
Анатольевна, П. С., Semionova, A. I., Komarov, Y., Алексахина, С. Н., Ivantsov, A. O., Iyevleva, A. G., & Имянитов, Е. Н. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0280-0 · Cited by 29
From Cancer Genomics to Precision Oncology—Tissue’s Still an Issue
Cohen, R. L., & Settleman, J. (2014) · Cell · doi:10.1016/j.cell.2014.05.027 · Cited by 32
Evolution of targeted therapies in cancer: opportunities and challenges in the clinic
Santhosh, S., Kumar, P. R. G., Ramprasad, V. L., & Chaudhuri, A. (2015) · Future Oncology · doi:10.2217/fon.14.198 · Cited by 32
Jung, G. W., Dover, D. C., & Salopek, T. G. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12694 · Cited by 29
Au, T. H., Wang, K., Stenehjem, D. D., & Garrido‐Laguna, I. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.01.04 · Cited by 32
Iizuka-Ohashi, M., Watanabe, M., Sukeno, M., Morita, M., Hoang, N. T. H., Kuchimaru, T., Kizaka‐Kondoh, S., Sowa, Y., Sakaguchi, K., Taguchi, T., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24696 · Cited by 30
Molnár, E., Garay, T., Donia, M., Baranyi, M., Rittler, D., Berger, W., Tímár, J., Grusch, M., & Hegedűs, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184484 · Cited by 30
Carcinoma of Unknown Primary Site
Jain, A., Tan, T. J. Y., & Tan, D. S. W. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1411384 · Cited by 29
Tumor Heterogeneity and Personalized Cancer Medicine: Are we Being Outnumbered?
Cirkel, G. A., Hooijdonk, C. G. G., Koudijs, M. J., Willems, S. M., & Voest, E. E. (2014) · Future Oncology · doi:10.2217/fon.13.214 · Cited by 36
Widemann, B. C., Acosta, M. T., Ammoun, S., Belzberg, A. J., Bernards, A., Blakeley, J. O., Bretscher, A., Cichowski, K. M., Clapp, D. W., Dombi, E., et al. (2014) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36312 · Cited by 29
Poschau, M., Dickreuter, E., Singh-Müller, J., Zscheppang, K., Eke, I., Liersch, T., & Cordes, N. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.06.005 · Cited by 28
Aziz, A. U. R., Farid, S., Qin, K., Wang, H., & Liu, B. (2018) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2018.1498903 · Cited by 28
Jiang, L., Li, R., Yan, F., Yap, T. A., & Yuan, Y. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106338 · Cited by 28
Targeting the Tumor-Tumor Microenvironment Crosstalk
Badve, S., & Gökmen‐Polar, Y. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2230362 · Cited by 28
The innovative evolution of cancer gene and cellular therapies
Lam, P., Khan, G. N., Stripecke, R., Hui, K. M., Kasahara, N., Peng, K.-W., & Guinn, B. (2013) · Cancer Gene Therapy · doi:10.1038/cgt.2012.93 · Cited by 32
How Many Diseases Are Colorectal Cancer?
Greystoke, A., & Mullamitha, S. (2012) · Gastroenterology Research and Practice · doi:10.1155/2012/564741 · Cited by 32
Appleman, V. A., Ahronian, L. G., Cai, J., Klimstra, D. S., & Lewis, B. C. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0340-t · Cited by 32
Luraghi, P., Bigatto, V., Cipriano, É., Reato, G., Orzan, F., Sassi, F. P., Bacco, F. D., Isella, C., Bellomo, S. E., Médico, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2151 · Cited by 29
Whitehead, C. E., Ziemke, E. K., Frankowski-McGregor, C. L., Mumby, R. A., Chung, J., Li, J., Osher, N., Coker, O., Baladandayuthapani, V., Kopetz, S., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00781-6 · Cited by 33
Addressing Challenges in Targeted Therapy for Metastatic Colorectal Cancer
Hage, M. E., Su, Z., & Linnebacher, M. (2025) · Cancers · doi:10.3390/cancers17071098 · Cited by 34
Epstein, R. J. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00304 · Cited by 28
Lombardo, R., Tosi, F., Nocerino, A., Bencardino, K. B., Gambi, V., Ricotta, R., Spina, F., Siena, S., & Bianchi, A. S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00533 · Cited by 27
Qu, F., Zhao, S., Cheng, G., Rahman, H., Xiao, Q., Chan, R. W. Y., & Ho, Y. (2021) · Microsystems & Nanoengineering · doi:10.1038/s41378-021-00267-w · Cited by 28
Molecular testing for colorectal cancer: Clinical applications
Имянитов, Е. Н., & Kuligina, E. S. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i10.1288 · Cited by 33
BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications
Angerilli, V., Sabella, G., Centonze, G., Lonardi, S., Bergamo, F., Mangogna, A., Pietrantonio, F., Fassan, M., & Milione, M. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103647 · Cited by 30
Small-molecule drugs of colorectal cancer: Current status and future directions
Yang, Y., Liu, P., Zhou, M., Yin, L., Wang, M., Liu, T., Jiang, X., & Gao, H. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166880 · Cited by 29
Jeong, W.-J., Cha, P.-H., & Choi, K.-Y. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i29.9862 · Cited by 28
Chemical Biology Tools for Regulating RAS Signaling Complexity in Space and Time
van Hattum, H., & Waldmann, H. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.001 · Cited by 29
Durability of Kinase-Directed Therapies—A Network Perspective on Response and Resistance
Murray, B. W., & Miller, N. L. G. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0088 · Cited by 29
Kim, B., Nam, S. W., Min, B. S., Ban, H. S., Paik, S., Lee, K., Im, J., Lee, Y., Park, J.-T., Kim, S., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0289-1 · Cited by 28
Immunostimulatory cytokine and doxorubicin co-loaded nanovesicles for cancer immunochemotherapy
Wu, T., Qiao, Q., Qin, X., Zhang, D., & Zhang, Z. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2019.02.008 · Cited by 28
Mutations in the Serine/Threonine Kinase BRAF: Oncogenic Drivers in Solid Tumors
Roa, P., Bremer, N. V., Foglizzo, V., & Cocco, E. (2024) · Cancers · doi:10.3390/cancers16061215 · Cited by 29
Metadata
- Authors
- Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R.
- Affiliations
- The Netherlands Cancer Institute (NL)
- University of Turin (IT)
- IFOM (IT)
- Corresponding author
- Bernards, René
- ORCID
- Venue
- Nature
- Published
- 2012-01-26
- Volume
- 483
- Issue
- 7387
- Pages
- 100-103
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2014881369
- Semantic Scholar
- 10564d8dc4a3ddb05a84b5a3ca8b7b622c5c17ea
- Cited by
- 2,051
- References
- 22
- Citations by year
- 2026: 75 · 2025: 81 · 2024: 106 · 2023: 145 · 2022: 126 · 2021: 168 · 2020: 145 · 2019: 117 · 2018: 139 · 2017: 129 · 2016: 149 · 2015: 215 · 2014: 188 · 2013: 172 · 2012: 91
- FWCI
- 105.49
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- European Commission (259015)
- Ministero della Salute
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- KWF Kankerbestrijding
- Associazione Italiana per la Ricerca sul Cancro (5 x mille)
- Regione Piemonte
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- BRAF V600E mutation, colon cancer, EGFR, vemurafenib, drug resistance, feedback activation, cetuximab, gefitinib, erlotinib, combination therapy, RNAi screen, melanoma, targeted therapy
- MeSH terms
- Cetuximab, Erlotinib Hydrochloride, Gefitinib, Vemurafenib, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Drug Synergism, Enzyme Activation, Female, Humans, Indoles, Melanoma, Quinazolines, Sulfonamides, Colorectal Neoplasms, Apoptosis, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Feedback, Physiological, RNA Interference, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Cell Proliferation, Mice, HEK293 Cells, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.